Elanco Animal Health Incorporated (NYSE:ELAN) Stock Position Increased by Harbor Capital Advisors Inc.

Harbor Capital Advisors Inc. grew its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 24.0% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,084,629 shares of the company's stock after purchasing an additional 209,734 shares during the period. Harbor Capital Advisors Inc. owned approximately 0.22% of Elanco Animal Health worth $13,135,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in ELAN. Commonwealth Equity Services LLC increased its holdings in Elanco Animal Health by 11.7% in the second quarter. Commonwealth Equity Services LLC now owns 34,942 shares of the company's stock valued at $504,000 after buying an additional 3,647 shares in the last quarter. TD Asset Management Inc raised its position in shares of Elanco Animal Health by 13.5% in the second quarter. TD Asset Management Inc now owns 379,342 shares of the company's stock valued at $5,474,000 after buying an additional 45,203 shares during the last quarter. Los Angeles Capital Management LLC purchased a new position in shares of Elanco Animal Health during the second quarter valued at approximately $170,000. Choreo LLC acquired a new position in Elanco Animal Health in the 2nd quarter valued at $620,000. Finally, Headlands Technologies LLC lifted its stake in shares of Elanco Animal Health by 2,484.4% during the 2nd quarter. Headlands Technologies LLC now owns 29,204 shares of the company's stock worth $421,000 after purchasing an additional 28,074 shares during the period. 97.48% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have issued reports on ELAN shares. Leerink Partnrs raised Elanco Animal Health to a "hold" rating in a research note on Monday, December 2nd. Stifel Nicolaus dropped their price target on shares of Elanco Animal Health from $20.00 to $18.00 and set a "buy" rating for the company in a research report on Tuesday. Barclays boosted their price objective on shares of Elanco Animal Health from $19.00 to $20.00 and gave the company an "overweight" rating in a research note on Friday, November 8th. Morgan Stanley cut shares of Elanco Animal Health from an "overweight" rating to an "equal weight" rating and reduced their price target for the company from $17.00 to $15.00 in a research report on Thursday, September 19th. Finally, Leerink Partners started coverage on shares of Elanco Animal Health in a research report on Monday, December 2nd. They issued a "market perform" rating and a $14.00 price objective for the company. One research analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus target price of $16.43.

Elanco Animal Health Stock Down 0.7 %

Shares of NYSE ELAN traded down $0.08 during midday trading on Friday, reaching $11.47. 5,032,792 shares of the company's stock were exchanged, compared to its average volume of 4,728,282. The stock has a market capitalization of $5.67 billion, a PE ratio of 28.68, a price-to-earnings-growth ratio of 1.96 and a beta of 1.41. Elanco Animal Health Incorporated has a 52-week low of $11.11 and a 52-week high of $18.80. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. The business's fifty day moving average price is $12.69 and its two-hundred day moving average price is $13.54.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.13 earnings per share for the quarter, topping analysts' consensus estimates of $0.12 by $0.01. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The business had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter last year, the company earned $0.18 earnings per share. The business's quarterly revenue was down 3.6% compared to the same quarter last year. Analysts forecast that Elanco Animal Health Incorporated will post 0.92 EPS for the current year.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.